NRAS and acute myeloid leukemia: The accumulation of additional mutations such as ASXL1, along with DNMT3A, RUNX1, SETBP1, NRAS, KRAS, CBL, and JAK2, is associated with increased proliferation, dysplasia, and progression to AML [7,9,20,21,22].